Ultragenyx Pharmaceutical (RARE) just cleared an important regulatory hurdle, with the UK Medicines and Healthcare products Regulatory Agency accepting its Marketing Authorisation Application for UX111 gene therapy targeting Sanfilippo syndrome Type A.
Against this regulatory backdrop, Ultragenyx Pharmaceutical’s share price has been under pressure. A 1-day share price return of 1.65% and a 7-day share price return of 2.95% have both declined, while a 30-day share price return of 4.26% contrasts with a much steeper 90-day share price decline of 39.91% and a 1-year total shareholder return decline of 51.46%. This points to short-term momentum trying to rebuild after a prolonged drawdown.
Scan 35 high quality undervalued stocks that, similar to Ultragenyx Pharmaceutical, pairs meaningful product catalysts with compressed share prices after heavy drawdowns.
Ultragenyx Pharmaceutical now trades well below both analyst targets and some intrinsic value estimates, even as UX111 advances and losses remain significant. Is the market prudence here excessive, or exactly on point, as you weigh valuation next?
Most Popular Narrative: 38% Undervalued
Ultragenyx Pharmaceutical last closed at $16.14, while the most followed narrative on Simply Wall St assigns a fair value of $26.00. This points to meaningful upside according to that framework and sets the scene for a more critical take on the current business model.
The "Ultragenyx Turnaround Thesis" is trapped in a commercial illusion, mistaking a multi-product portfolio for financial stability while ignoring deep-rooted structural inefficiencies.
Here is why the market is mispricing the friction inside RARE’s operational engine:
See why 2 investors see Ultragenyx Pharmaceutical as 38% undervalued.
Result: Fair Value of $26.00 (UNDERVALUED)
Still, Ultragenyx Pharmaceutical could pressure this bearish thesis if UX111 or other late stage programs secure approvals on workable terms that reshape the revenue mix and cash burn.
Find out about the key risks to this Ultragenyx Pharmaceutical narrative.
Another View On Ultragenyx Pharmaceutical’s Value
That narrative pegs Ultragenyx Pharmaceutical at a fair value of $26.00, but the market is sending a very different message through the current P/S ratio of 2.2x. The same 2.2x level appears as the fair ratio, while US Biotechs and direct peers both sit near 9.5x to 9.7x.
This kind of gap can cut both ways. It can reflect an opening for patient investors if the business model improves, or a sign that the market is still pricing in balance sheet stress and ongoing losses. Which explanation feels more convincing when you weigh your own risk limits?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment around Ultragenyx Pharmaceutical is clearly split, with sharp drawdowns contrasted with progressing assets and a mix of caution and optimism in the data. Act promptly, review both sides of the argument, and pressure test your own thesis against the 2 key rewards and 3 important warning signs.
Looking For More Investment Ideas Beyond Ultragenyx Pharmaceutical?
If Ultragenyx Pharmaceutical has you thinking harder about risk and reward, do not stop there. Broader opportunity often sits just outside your current watchlist.
Scan fresh potential in companies with compressed valuations and stronger fundamentals using the 35 high quality undervalued stocks.
- Target resilient balance sheets that can better withstand shocks by moving through the list of solid balance sheet and fundamentals (24 results).
- Hunt for lesser known businesses with robust financials before they attract wider attention by reviewing the 20 high quality undiscovered gems.
- Prioritise stability first and focus on companies that score well on risk using the 30 resilient stocks with low risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com